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Abstract
Background: In October 2007, the working group CEN/TC 216 of the European Committee for standardisation
suggested that the Sabin oral poliovirus vaccine type 1 strain (LSc-2ab) presently used for virucidal tests should be
replaced by another attenuated vaccine poliovirus type 1 strain, CHAT. Both strains were historically used as oral
vaccines, but the Sabin type 1 strain was acknowledged to be more attenuated. In Germany, vaccination against
poliomyelitis was introduced in 1962 using the oral polio vaccine (OPV) containing Sabin strain LSc-2ab. The
vaccination schedule was changed from OPV to an inactivated polio vaccine (IPV) containing wild polio virus type
1 strain Mahoney in 1998. In the present study, we assessed potential differences in neutralising antibody titres to
Sabin and CHAT in persons with a history of either OPV, IPV, or OPV with IPV booster.
Methods: Neutralisation poliovirus antibodies against CHAT and Sabin 1 were measured in sera of 41 adults
vaccinated with OPV. Additionally, sera from 28 children less than 10 years of age and immunised with IPV only
were analysed. The neutralisation assay against poliovirus was performed according to WHO guidelines.
Results: The neutralisation activity against CHAT in adults with OPV vaccination history was significantly lower than
against Sabin poliovirus type 1 strains (Wilcoxon signed-rank test P < 0.025). In eight sera, the antibody titres
measured against CHAT were less than 8, although the titre against Sabin 1 varied between 8 and 64. Following
IPV booster, anti-CHAT antibodies increased rapidly in sera of CHAT-negative adults with OPV history. Sera from
children with IPV history neutralised CHAT and Sabin 1 strains equally.
Conclusion: The lack of neutralising antibodies against the CHAT strain in persons vaccinated with OPV might be
associated with an increased risk of reinfection with the CHAT polio virus type 1, and this implies a putative risk of
transmission of the virus to polio-free communities. We strongly suggest that laboratory workers who were
immunised with OPV receive a booster vaccination with IPV before handling CHAT in the laboratory.
Background
To prevent and control the spread of nosocomial viral
infections, disinfectants with proven virucidal efficacy
must be used. Therefore, disinfectants must pass a viru-
cidal activity test performed in compliance with good
laboratory practise and country-specific standards. For
instance, the European Committee for Standardization
Technical Committee 216 - Chemical Disinfectants and
Antiseptics (CEN/TC 216) developed a European stan-
dard that comprises a virucidal quantitative suspension
test for chemical disinfectants and antiseptics used in
human medicine (EN 14476:2005+A1:2006) [1]. Accord-
ing to the European standard EN 14476, Sabin polio-
virus type 1 vaccine LSc-2ab is one of the test viruses.
Generally, small non-enveloped viruses such as picorna-
viruses are very resistant to biocides. Therefore, polio-
virus has been most widely used for virucidal testing. In
October 2007, during a plenary meeting of the working
group CEN/TC 216, it was suggested that the Sabin
poliovirus type 1 vaccine LSc-2ab should be replaced by
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therefore were difficulties in the availability of the Sabin
strain LSc-2ab in some European countries. In
Germany, the virus can be obtained from the German
Association for the Control of Viral Diseases [Deutsche
Vereinigung zur Bekämpfung der Viruskrankheiten
(DVV)]. Another source is the National Institute for
Biological Standards and Control (NIBSC), offering the
WHO reference strain Sabin Original Virus, second pas-
sage (SO+2) (NIBSC, code 01/528). In our laboratory,
the original Sabin virus obtained from Behringwerke AG
is used. In this study we used strains from all these
three different sources to show that their properties are
identical. Both attenuated vaccine strains for poliovirus
type 1, CHAT and Sabin, were derived from the wild
Mahoney strain. During the 1950 s, several virus var-
iants were derived from the Mahoney strain by succes-
sive passages in various in vivo and in vitro cell
substrates and selected for reduced neurovirulence in
monkeys, to be used as vaccines [2-4]. Three live polio-
virus type 1 vaccine strains have been generated. The
best-known vaccine strain is probably the Sabin polio-
virus type 1 strain (LSc-2ab), developed by Albert Bruce
Sabin at the University of Cincinnati College of Medi-
cine and Children’s Hospital Research Foundation. The
CHAT vaccine strain was produced by Hilary Koprowski
at The Wistar Institute of Anatomy and Biology, Phila-
delphia. The CHAT virus and the third vaccine strain,
Cox (also named the Lederle SM strain), are derived
from a common progenitor SM N-90 strain and are
genotypically more closely related to each other than to
the Sabin virus LSc-2ab [4]. Both CHAT and Cox
strains exhibit a higher degree of neurovirulence than
Sabin 1 [4,5]. Because of the superior immunogenic and
safety profile of Sabin strains, their use was widely
recommended for oral polio vaccination (OPV) [5,6].
Jonas Salk, at the University of Pittsburgh, took a differ-
ent approach and developed an inactivated poliovirus
vaccine (IPV). The poliovirus strain used by Salk and still
used by most manufacturers is poliovirus type 1 Maho-
ney. The Salk polio vaccine was introduced worldwide in
1955, but in the early 1960 s, IPV was replaced by OPV
in many countries. In contrast to other European coun-
tries, in particular the Netherlands, Denmark, and the
UK, IPV was not successfully implemented in Germany
at this time and reached only 5 percent of its population
in 1960. Wide vaccination against poliomyelitis was
introduced in 1962 using the OPV containing Sabin
strain LSc-2ab [7]. Germany changed from an OPV to an
IPV vaccination schedule in 1998 because of the risk of
vaccine-associated paralytic polio (VAPP). Between 1990
and 1999, 15 cases of VAPP had been registered in Ger-
many [8]. IPV use, which carries no risk of VAPP,
increased after 1999 also in other European countries
and in the USA [9,10]. The majority of our laboratory
staff was vaccinated before 1998 with Sabin strain LSc-
2ab. In a previous study, the immunity status of 10 mem-
bers of the laboratory staff with OPV history against
CHAT was analysed using neutralisation test to estimate
the potential risk of laboratory-associated infections and
transmission to the community. Seven of the samples
had the antibody titres against CHAT more than twofold
lower than those against poliovirus type 1 Sabin, and
three of them had the titres le s st h a n8[ 1 1 ] .I nt h ef o l -
lowing study we expanded the study group and compared
immunity against CHAT and Sabin in adults with OPV
history and in children vaccinated with IPV.
Methods
Serum samples
A total of 78 sera from 69 donors were used for this
study.
Adults
Group I included sera from 41 adults. Sera from 29
adults were submitted to our laboratory in 2009 for
determination of immunity status to poliovirus. Their
vaccination history is not known, but we assumed, that
they were vaccinated with OPV as the majority of Ger-
man people born before 1998. In addition, sera from 12
laboratory workers potentially exposed to poliovirus were
obtained between 2008 and 2009 by an occupational
health physician according to the examination program
of the German Workers Compensation Act (G 42 “Activ-
ities with a risk of infection”) .T h es e r aw e r es t o r e da t
-20°C prior to testing. All laboratory workers provided
written and/or oral informed consent prior testing. Ten
laboratory workers were vaccinated with OPV only, from
four to seven times according to the records in their
immunization record cards. The vaccination history of
three representative cases according to the immunization
record card is given in Table 1. Schematic representation
of the vaccination history of two other workers, who
were vaccinated with both OPV and IPV is presented in
Table 2. Nine sera from laboratory workers were sent to
other laboratories to validate the results.
Children
Group II consisted of 28 samples from children born
after 1998, aged 1 to 10 years. Their sera were submitted
to our laboratory in 2009 for determination of immunity
status to poliovirus. Since 1998, only IPV is recom-
mended to use in Germany. Therefore, we assumed, that
these children had been vaccinated with IPV.
The study was carried out in compliance with the Hel-
sinki Declaration. None of the samples was collected for
study purposes. Discarded sera from our routine diag-
nostics were de-identified. Sera from laboratory workers
were coded. All samples were tested in an anomysed
fashion. Ethical approval was not required.
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The following poliovirus type 1 strains of passages 2-3
were used for challenge:
- Sabin original virus, second passage (SO+2) (Beh-
ringwerke AG, Marburg, Germany)
-W H Or e f e r e n c ev i r u s ,S a b in original, second pas-
sage (NIBSC, code 01/528, Hertfordshire, UK)
- DVV reference virus, Sabin original, second pas-
sage (LSc-2ab) manufactured by Chiron-Behring,
Marburg (Eurovir, Luckenwalde, Germany)
- CHAT strain (ATCC, catalogue no. VR-1562)
Microneutralisation assay
Neutralising titres against poliovirus were detected
according to WHO guidelines [12]. All serum samples
were heat-inactivated (56°C/30 min). Sera and the posi-
tive and negative controls were serially two-fold diluted
from 2 to 1024, and 25 μl of challenge virus was added
to 25 μl of serum dilution, followed by incubation for
3h o u r si naC O 2 incubator. The challenge virus con-
tained 100 TCID50 (range 50-200 TCID50/ml). After
adding 0.1 ml of Hep2 cell suspension (European
Collection of Cell Cultures, Salisbury, UK, used between
passages 5 and 30), the plates were incubated in a CO2
i n c u b a t o ra t3 6 ° Cf o r5d a y s .A f t e rs t a i n i n gw i t hc r y s t a l
violet, plates were dried and read visually. Each test
serum was investigated in duplicate on at least two
separate occasions, and their titres did not vary more
than two-fold between and within the assays. Reciprocal
geometric mean titres (GMT) for each patient serum
were calculated using all measured results. An in-house
reference serum was included in each test run to con-
vert the serum titres into international units (IU) and to
control the reproducibility of results. Calibration of the
in-house reference serum was carried out against the
2nd International Standard Poliovirus Antiserum (code
66/2020, NIBSC, Hertfordshire, UK) containing 25 IU
for poliovirus type 1. For this purpose, the in-house
Table 1 Results of neutralization test with CHAT and Sabin 1 strains in paired sera of three laboratory workers with
low antibody titers post OPV and four weeks later after IPV booster
No. Year of birth Vaccination history IPV booster
10/2009
Poliovirus Type 1
Strain CHAT
ATTC VR-1562
Poliovirus Type 1
Strain Sabin (LSc-2ab)
Behringwerke AG
GMT* (IU/ml) GMT (IU/ml)
5a 1979 OPV: before < 8 (< 1,1) 32 (1,7)
5b 10/1979 after 512 (71,2) 3649 (281,1)
01/1980
02/1981
02/1991
6a 1959 OPV: before < 8 (< 1,1) 32 (1,7)
6b vaccination5 xin Russia after 287 (39,9) 1625 (125,2)
8a 1966 OPV: before < 8 (< 1,1) 16 (0,8)
8b 05/1966 after 575 (79,9) 575 (44,3)
07/1966
08/1966
11/1972
01/1973
11/1978
01/1993
GMT* Reciprocal geometric mean titers
Table 2 Immunization record of two laboratory workers vaccinated with OPV and IPV
No. Year of
birth
date of vaccination Poliovirus Type 1 Strain
CHAT
Poliovirus Type 1 Strain Sabin
(LSc-2ab)
ATTCVR-1562
GMT (IU/ml)
WHO-reference virus
GMT (IU/ml)
28 1962 IPV: 04/1964, 06/1964, 09/1964
OPV: 10/1964, 12/64, 04/1964, 01/1971, 03/82
35 (4.9) 64 (3.4)
34 1985 Until 1991 OPV vaccination in Russia,
OPV: 04/1985, 05/1985, 07/1985, 01/1986, 03/1986, 02/1987, 03/
1987, 11/1996
IPV: 02/2002
256 (35.5) 512 (27.5)
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Poliovirus Antiserum were titrated in parallel on six
separate occasions.
Statistics
Comparison of the data from two groups was accom-
plished by using Wilcoxon’ss i g n e d - r a n kt e s ta n d
SYSTAT statistics computer software. Significance was
defined as achieving a P value of 0.05.
Results
Calibration of in-house reference serum in international
units
The GMT of the International Standard Antiserum and
of the in-house reference serum calculated from all
measured results obtained with strain Sabin from Beh-
ringwerke were 324 and 74, respectively. Accordingly, as
the International Standard Antiserum contained 25 IU/
ml, the potency of the in-house reference serum was 74/
324 × 25 = 5.7 IU/ml. The geometric mean titre of the
in-house reference serum was 55 in a neutralisation test
against DVV Sabin 1 reference virus, 106 against WHO
Sabin 1 reference virus, and 40 against CHAT. These
titres were used to transform the results obtained with
these strains into international units per millilitre.
A more than four-fold difference in the titre values
achieved with different strains was considered signifi-
cant. This was based, on the fact that the geometric
mean titre of the in-house reference serum against
WHO Sabin 1 reference virus was approximately two-
fold higher than against the CHAT strain, and on the
other hand, the fact that the acceptable range of neutra-
lisation titres should be within one two-fold dilution, as
recommended by the WHO [12].
Poliovirus neutralising antibodies in adults
There was no significant difference between neutralis-
ing antibody titres found in the 41 sera from adults
with three different stocks of the Sabin poliovirus type
1 strain when examined by the Wilcoxon signed-rank
test (P > 0.25) (Figure 1). The antibody titre of each
serum tested with different stocks of the Sabin polio-
virus type 1 strain varied no more than three-fold. In
contrast, the neutralisation activity against CHAT was
significantly lower than against stocks of Sabin polio-
virus type 1 (Wilcoxon signed-rank test P < 0.025). In
13 sera, the antibody titre against CHAT was fivefold
and more lower than that against poliovirus type 1
Sabin. In eight sera, the titres against CHAT were even
less than 8 (Table 3). However, in approximately half
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Figure 1 Neutralizing antibodies against different strains of poliomyelitis virus type 1 in adults. The boxplots show the 10th, 25th, 50th
(median), 75th and 90th percentiles. The circles indicate outlier observations.
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Page 4 of 9Table 3 Results of neutralization test with different poliovirus type 1 challenge strains in adults immunized totally or
partially with OPV.
Poliovirus Type 1
Strain CHAT
Poliovirus Type 1 Strain Sabin (LSc-2ab)
ATTC
VR-1562
WHO reference virus Behringwerke AG DVV reference virus
Case No. Age Ratio* GMT* (IU/ml) GMT (IU/ml) GMT (IU/ml) GMT (IU/ml)
1 16 < 8 (< 1,1) 11 (0,6) 11 (0,8) 8 (0,8)
2 29 < 8 (< 1,1) 16 (0,8) 19 (1,5) 11 (1,1)
3 24 < 8 (< 1,1) 16 (0,8) 19 (1,5) 8 (0,8)
4 33 < 8 (< 1,1) 8 (0,4) 8 (0,6) < 8 (< 1,1)
5 29 < 8 (< 1,1) 32 (1,7) 53 (4,1) 32 (3,3)
6 49 < 8 (< 1,1) 32 (1,7) 19 (1,5) 16 (1,6)
7 42 < 8 (< 1,1) 45 (2,4) 45 (3,5) 64 (6,6)
8 43 < 8 (< 1,1) 16 (0,8) 11 (0,8) 11 (1,1)
9 50 8 8 (1,1) 64 (3,4) 16 (1,2) 32 (3,3)
10 53 11 8 (1,1) 90 (4,8) 53 (4,1) 32 (3,3)
11 10 11 16 (2,2) 181 (9,7) 256 (19,7) 181 (18,7)
12 37 10 17 (2,4) 181 (9,7) 76 (5,9) 128 (13,2)
13 40 17 28 (3,9) 512 (27,5) 362 (27,9) 256 (26,5)
14 31 8 32 (4,4) 256 (13,7) 152 (11,7) 256 (26,5)
15 40 32 32 (4,4) 1024 (55) 362 (27,9) 362 (37,5)
16 44 5 45 (6,2) 256 (13,7) 181 (13,9) 181 (18,7)
17 40 11 64 (8,8) 724 (38,9) 430 (33,1) 724 (75)
18 28 5 128 (17,7) 724 (38,9) 304 (23,4) 256 (26,5)
19 18 5 128 (17,7) 724 (38,9) 512 (39,4) 512 (53)
20 37 8 128 (17,7) 1024 (55) 861 (66,3) 512 (53)
21 49 8 128 (17,7) 1024 (55) 1024 (78,9 1024 (106,1)
22 41 4 8 (1,1) 32 (1,7) 32 (2,5) 22 (2,3)
23 43 4 8 (1,1) 32 (1,7) 26 (2,0) 22 (2,3)
24 25 1 16 (2,2) 16 (0,8) 22 (1,7) 16 (1,6)
25 59 4 16 (2,2) 64 (3,4) 38 (2,9) 32 (3,3)
26 54 1 32 (4,4) 32 (1,7) 26 (2,0) 16 (1,6)
27 64 2 32 (4,4) 64 (3,4) 53 (4,1) 22 (2,3)
28 46 1 35 (4,9) 64 (3,4) 64 (4,9) 64 (6,6)
29 60 1 64 (8,8) 90 (4,8) 76 (5,9) 90 (9,3)
30 29 2 64 (8,8) 181 (9,7) 181 (13,9) 64 (6,6)
31 60 2 128 (17,7) 256 (13,7) 215 (16,6) 181 (18,7)
32 46 2 128 (17,7) 256 (13,7) 152 (11,7) 128 (13,2)
33 36 2 128 (17,7) 362 (19,4) 256 (19,7) 256 (6,5)
34 24 2 256 (35,5) 512 (27,5) 512 (39,4) 512 (53)
35 28 4 256 (35,5) 1024 (55) 724 (55,8) 512 (53)
36 37 2 512 (71,1) 1024 (55) 1024 (78,9) 1024 (106,1)
37 58 2 512 (71,1) 1024 (55) 1024 (78,9) 724 (75)
38 35 1 1024 (142,3) 1024 (55) 724 (55,8) 1024 (106,1)
39 36 1 1024 (142,3) 1024 (55) 861 (66,3) 724 (75)
40 40 1 1024 (142,3) 1024 (55) 1024 (78,9) 1024 (106,1)
41 61 1 1024 (142,3) 1024 (55) 1024 (78,9) 1024 (106,1)
The sera were grouped as follows:
In sera No. 1 to 8 antibody titres against the strain CHAT were lower than 1: 8.
In sera No. 9 to 21 antibodies titre against the strain CHAT were five or more fold lower than against the strain Sabin.
In sera from No. 22 to 41 the difference between antibodies titre against the strain CHAT and the strain Sabin was fourfold and less.
Case numbers in Tables 1 and 2 correspond to the case numbers in Table 3.
*Ratio of titre against Sabin 1 WHO reference strain to titre against CHAT.
**GMT Reciprocal geometric mean titers.
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anti-Sabin 1 antibody concentration was not more
than four-fold.
Only an one or two-fold difference between anti-
CHAT and anti-Sabin 1 titres was found in the sera of
two laboratory workers who had a history of mixed
OPV and IPV vaccination (Table 2).
Three laboratory workers vaccinated with OPV, from
four to seven times according to the records in their
immunization record cards, had antibody titres against
CHAT under 8. Their antibody titres increased signifi-
cantly after booster vaccination with IPV (Table 1).
Sera from nine laboratory workers were sent to the
national reference laboratory for polio- and entero-
viruses at the Robert Koch Institute (RKI) in Berlin and
to the Institute for Medical Virology, Johann Wolfgang
Goethe University, Frankfurt, to verify our results. The
obtained data are presented in Table 4. Case numbers
in Table 4 correspond to the case numbers in Table 3.
Some sera had been used up in the first experiments, so
the paired sera were collected. In Table 1 and 4, these
sera are marked with the letter b. All laboratories mea-
sured lower anti-CHAT than anti-Sabin 1 titres in both
their internal reference sera and patient sera. To recal-
culate the RKI results from titres to international units,
the GMT of the RKI internal in-house reference serum
tested with Sabin 1 (140) and CHAT (48) on six sepa-
rate occasions according to WHO recommendations
was used [12]. The RKI internal in-house reference
serum had been calibrated earlier against the 2nd
International Standard Poliovirus Antiserum with a
result of 3.0 IU/ml [13]. Transformation of the titre
values obtained in the Institute for Medical Virology of
Frankfurt to international units was performed using the
internal in-house reference serum of the laboratory of
Prof. Enders. This in-house reference calibrated earlier
against the International Standard Antiserum as
described above was included in every assay run in
Frankfurt. The GMT of the serum calculated from all
measured results was 22 for CHAT and 86 for Sabin 1.
A greater than four-fold difference was observed in
international unit values between anti-CHAT and anti-
Sabin 1 neutralisation antibodies in sera nos. 7b, 13b,
and 21.
Poliovirus neutralising antibodies after history of IPV in
children
The 28 sera from children equally neutralised CHAT
und Sabin strains (Wilcoxon signed-rank test P > 0.1)
(Table 5; Figure 2).
Discussion
The neutralising antibody test is the method of choice
to determine the immune status against poliovirus.
Although the precise concentration of antibodies that is
necessary for protection is unknown, it is accepted that
any level of type-specific neutralisation of infection in
cell culture is protective [14]. In the WHO Manual for
the virological investigation of polio, titration of sera
from 8 to 1024 is recommended [1]. Therefore, in
Table 4 Results of neutralization test with poliovirus type 1 strain CHAT and Poliovirus Type 1 Strain Sabin (LSc-2ab)
in three different laboratories
Laboratory Nr. 1 Laboratory Nr. 2 Laboratory Nr. 3
Case
No.
CHAT
ATTC
VR-1562
Sabin 1
WHO reference
strain
Ratio* CHAT
ATTC
VR-1562
Sabin 1
WHO reference
strain
Ratio CHAT
ATTC
VR-1562
Sabin 1
WHO reference
strain
Ratio
GMT** (IU/
ml)
GMT (IU/ml) GMT IU/ml GMT IU/ml GMT IU/
ml
GMT IU/ml
7b < 8 (< 1,1) 91 (4,9) > 4,5 12 (0,6) 192 (4,1) 7,1 <10 (<1,3) 80 (5,3) > 4,1
9 8 (1,1) 64 (3,4) 3,1 32 (1,5) 128 (2,7) 1,8 <10 (<1,3) 40 (2,7) > 2,0
12b 23 (3,2) 362 (19,5) 6,1 64 (3,1) 256 (5,5) 1,8 10 (2,6) 160 (10,6) 4,1
13b 32 (4,4) > 786 (> 42,3) > 9,4 48 (2,3) > 512 (> 11) > 4,7 20 (5,2) 640 (42,4) 8,2
28b 32 (4,4) 64 (3,4) 0,8 96 (4,6) 128 (2,7) 0,6 20 (5,2) 40 (2,7) 0,5
16b 64 (8,9) 512 (27,5) 3,1 128 (6,2) 512 (11,0) 1,8 20 (5,2) 320 (21,2) 4,1
21 128 17,8 2048 110,1 6,2 384 (18,6) > 512 (> 11) > 0,6 40 (10,4) 1280 (84,8) 8,2
8b 256 (35,6) 362 (19,5) 0,5 512 (24,8) 512 (11,0) 0,4 80 (20,7) 320 (21,2) 1,0
34b 256 (35,6) > 786 (> 42,3) > 1,9 > 512 (>
25)
> 512 (> 11) - 80 (20,7) 320 (21,2) 1,0
Internal
control
41 (5,7) 106 (5,7) 1,0 62 (3) 140 (3) 1,0 22 (5,7) 86 (5,7) 1,0
Laboratory Nr. 1 - Labor Enders, Stuttgart, Laboratory Nr. 2 - Robert Koch-Institute (RKI), Berlin, Laboratory Nr. 3 - Institute for Medical Virology, Johann Wolfgang
Goethe-University of Frankfurt.
*Ratio of IU/ml Sabin to IU/ml CHAT.
**GMT Reciprocal geometric mean titers.
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adults were protected against the poliovirus type 1 Sabin
strains. In contrast, one-fifth of the tested adult persons
had an antibody titre against CHAT under 8 and pre-
sumably were not protected. Obviously, the difference
between neutralising titres against type 1 Sabin strain
and CHAT base on the antigenic properties of strains
and not on the variations in test performance such as
viral dose and fluctuations in the titre of antibodies.
This claim is supported by the fact that the adults were
protected against all three type 1 Sabin strains from dif-
ferent sources but not against CHAT.
In addition, one-fourth of the CHAT positive sera had
an antibody titre against CHAT four-fold and more
lower than that against Sabin (nos. 8-18). Other labora-
tories also confirmed lower titre for CHAT in several
samples. Moreover, the titre values measured by
different laboratories were transformed into interna-
tional units because the use of relative potency reduces
the variation between laboratories, in contrast to direct
titre estimation [15]. However, the relative potencies to
Sabin 1 of two samples (7b and 13b) (Table 4) were still
more than four-fold higher than to CHAT.
The fact, that the OPV Sabin strain-induced antibo-
dies neutralise better the Sabin strain than the CHAT
strain can be explained by the antigenic differences in
these strains. The immunogenicity of poliovirus is deter-
mined by four distinct sites. The analysis of antigenic
structures of CHAT and Mahoney with a panel of Sabin
1 neutralising monoclonal antibodies shows, that neither
Mahoney or CHAT strains were neutralised by three
antibodies against sites 1 and 3. CHAT alone did not
react with two antibodies against site 2a. The results
were consistent with known amino acid differences in
Table 5 Results of neutralization test with different poliovirus type 1 challenge strains in 28 children immunized
with IPV
Poliovirus Type 1 Strain CHAT Poliovirus Type 1 Strain Sabin (LSc-2ab)
ATTC
VR-1562
WHO-reference virus DVV-reference virus Behringwerke AG
Case No. Age Ratio* GMT** IU/ml GMT IU/ml GMT IU/ml GMT IU/ml
42 8 < 8 < 8 23 1,3 11 0,9 16 1,7
43 10 1 11 1,7 11 0,6 11 0,9 8 0,9
44 9 2 11 1,7 27 1,5 18 1,5 11 1,2
45 6 1 16 2,4 19 1,1 20 1,6 11 1,2
46 5 1 16 2,4 23 1,3 23 1,8 16 1,7
47 9 2 19 2,9 38 2,2 25 2,1 27 2,9
48 3 2 25 3,8 51 2,9 37 3,0 32 3,5
49 5 1 32 4,8 32 1,8 23 1,8 23 2,5
50 9 1 32 4,8 45 2,6 32 2,6 32 3,5
51 8 2 32 4,8 64 3,6 64 5,2 45 4,9
52 8 2 32 4,8 64 3,6 64 5,2 45 4,9
53 10 3 32 4,8 91 5,1 64 5,2 64 7,0
54 5 3 32 4,8 81 4,6 97 7,9 51 5,5
55 8 4 32 4,8 128 7,2 128 10,4 91 9,9
56 4 3 45 6,8 128 7,2 128 10,4 64 7,0
57 8 2 64 9,6 128 7,2 64 5,2 32 3,5
58 10 1 64 9,6 64 3,6 91 7,3 45 4,9
59 2 1 91 13,6 91 5,1 45 3,7 45 4,9
60 3 1 128 19,2 181 10,2 181 14,7 91 9,9
61 8 1 181 27,2 181 10,2 128 10,4 64 7,0
62 3 1 181 27,2 256 14,5 256 20,8 181 19,7
63 3 3 181 27,2 512 29,0 256 20,8 181 19,7
64 9 3 181 27,2 512 29,0 512 41,5 256 27,9
65 8 3 181 27,2 512 29,0 724 58,7 362 39,5
66 1 2 203 30,5 406 23,0 223 18,1 161 17,6
67 4 2 256 38,4 512 29,0 256 20,8 181 19,7
68 4 1 724 108,6 1024 58,0 1024 83,0 1024 111,7
69 1 1 1024 153,6 1024 58,0 724 58,7 1024 111,7
*Ratio of titre against Sabin 1 WHO reference strain to titre against CHAT.
**GMT Reciprocal geometric mean titers.
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Page 7 of 9these sites [16]. A clear difference between reactivity of
inactivated Mahoney and live Sabin 1 was also demon-
strated by monoclonal antibody-based block-ELISA [17].
Our findings raise the question of whether persons
with low levels of neutralising antibodies to Sabin 1 are
protected against reinfection with the CHAT strain. In
the early years of polio vaccine development, many stu-
dies were carried out to determine the protective levels
of polio antibodies [18]. Different studies indicated that
persons with low serum neutralising antibody titres can
be reinfected with wild as well with vaccine virus [19-22].
On the other hand, these studies suggested that persons
with low but detectable antibodies are probably not in
danger of developing clinical poliomyelitis. The lifelong
protection to poliomyelitis when the titre falls below
detectability can be explained with immunological mem-
ory. The secondary response to infection seems to be
rapid enough to protect against paralytic disease. However,
a more recent study carried out in 2005 in the Netherlands
demonstrated that poliovirus-specific memory immunity
in seronegative elderly people does not protect against
virus excretion [23]. Abbink et al. challenged 429 elderly
people with monovalent oral poliovirus vaccine (type 1
or 3) and followed immune response and virus excretions
for 8 weeks. Most seronegative participants (81%) excreted
poliovirus type 1 for 3 to 49 days. A neutralising effect of
preexisting antibodies could be clearly seen: only 17% of
prevaccinated and 22% of the naturally immunised per-
sons excreted poliovirus type 1. Moreover, the period of
excretion was shorter in persons with preexisting immu-
nity (maximum 28 days). However, this indicates that
immunised laboratory workers with low antibody titres
can be reinfected with CHAT and may be a source of
infection to others who have not been vaccinated. Because
CHAT is characterised by a lower degree of attenuation
and temperature-sensitivity than Sabin 1 and also shows
molecular and biological properties closer to wild polio-
virus strain, it has been strongly recommended that
laboratories always use Sabin 1 from material that com-
plies with WHO requirements for the production of oral
polio vaccine [Martin J personal communication]. Such
preparations are available from the National Institute for
Biological Standards and Control (NIBSC), a centre of the
Health Protection Agency (HPA) in the United Kingdom
(ref. N0. 01/528, contact: Javier.Martin@nibsc.hpa.org.uk).
In our study, anti-CHAT antibodies increased rapidly
after IPV booster in sera of three of the workers with OPV
history. Moreover, children immunised with IPV had the
same level of antibodies against CHAT as against Sabin 1.
This result supplies an additional argument for the benefit
of IPV using Mahoney strain, considering that CHAT is
more similar to wild virus than Sabin 1, the one used for
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Figure 2 Neutralizing antibodies against different strains of poliomyelitis virus type 1 in children. The boxplots show the 10th, 25th, 50th
(median), 75th and 90th percentiles. The circles indicate outlier observations.
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Page 8 of 9OPV. However, this conclusion has some limitations, since
the study does not include similar subject groups: OPV in
adults, versus IPV for children. Some adults were probably
vaccinated a long time ago. There are different arguments
for and against using of OPV or IPV. According WHO
recommendations, during the pre-eradication period the
national choice of vaccines must include OPV or IPV, or a
combination of both [24].
Conclusion
In any case, laboratory workers should be boostered with
IPV before working with CHAT if it is not possible to
avoid the use of CHAT for the research aims. The use of
the CHAT strain would not comply to current require-
ments for the containment of poliovirus recommended
by WHO [25]. CHAT should not be used for any stan-
dard laboratory assays including determination of viruci-
dal efficiency. At the same time, it should be considered
to replace poliovirus with an other virus (e.g. Echovirus 1
or an animal parvovirus), to test the virucidal efficacy of
disinfectants. The use of poliovirus will be more
restricted after eradication. Therefore, the validation of
virucidal tests using another virus strain should be
started as soon as possible.
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